UROTHELIAL CARCINOMA

This study tested whether giving two drugs (toripalimab and gemcitabine) before surgery could shrink tumors in people with muscle-invasive bladder cancer who could not receive standard chemotherapy. It involved 50 participants at a single hospital in China. The goal was to see if…

This study tested several different immunotherapy drug combinations for people with advanced bladder cancer that had worsened after standard chemotherapy. It involved 272 participants and was designed to quickly find which combinations were most effective and safe. The goal was t…

This early-stage study tested whether a patient's own immune cells could be genetically modified in a lab to recognize and attack cancer cells, then safely given back to the patient. It involved 10 adults with specific types of bladder, skin (melanoma), or head and neck cancers w…

This study tested whether adding the drug lenvatinib to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced bladder cancer who cannot tolerate standard chemotherapy. It involved 505 participants and aimed to see if the combination helped…

This early-stage study tested whether combining an immunotherapy drug (avelumab) with a chemotherapy drug (docetaxel) is safe and effective for people with advanced bladder cancer that has spread. The trial specifically focused on patients whose cancer didn't respond to standard …

This early-stage study aimed to find a safe and effective dose of a new drug called TPST-1495, given alone or with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors. It enrolled 89 adults with cancers like colorectal, lung, and head and neck cancer …

This study aimed to understand why some patients with advanced bladder cancer respond well to immunotherapy while others do not. Researchers analyzed stool and blood samples from 40 patients to see if differences in their gut bacteria could predict treatment success. The goal was…